Detectability and structural stability of a liquid fiducial marker in fresh ex vivo pancreas tumour resection specimens on CT and 3T MRI
Tóm tắt
To test the detectability of a liquid fiducial marker injected into ex vivo pancreas tumour tissue on magnetic resonance imaging (MRI) and computed tomography (CT). Furthermore, its injection performance using different needle sizes and its structural stability after fixation in formaldehyde were investigated. Liquid fiducial markers with a volume of 20–100 µl were injected into freshly resected pancreas specimens of three patients with suspected adenocarcinoma. X‑ray guided injection was performed using different needle sizes (18 G, 22 G, 25 G). The specimens were scanned on MRI and CT with clinical protocols. The markers were segmented on CT by signal thresholding. Marker detectability in MRI was assessed in the registered segmentations. Marker volume on CT was compared to the injected volume as a measure of backflow. Markers with a volume ≥20 µl were detected as hyperintensity on X‑ray and CT. On T1- and T2-weighted 3T MRI, marker sizes ranging from 20–100 µl were visible as hypointensity. Since most markers were non-spherical, MRI detectability was poor and their differentiation from hypointensities caused by air cavities or surgical clips was only feasible with a reference CT. Marker backflow was only observed when using an 18-G needle. A volume decrease of 6.6 ± 13.0% was observed after 24 h in formaldehyde and, with the exception of one instance, no wash-out occurred. The liquid fiducial marker injected in ex vivo pancreatic resection specimen was visible as hyperintensity on kV X‑ray and CT and as hypointensity on MRI. The marker’s size was stable in formaldehyde. A marker volume of ≥50 µL is recommended in clinically used MRI sequences. In vivo injection is expected to improve the markers sphericity due to persisting metabolism and thereby enhance detectability on MRI.
Tài liệu tham khảo
Van der Horst A, Lens E, Wognum S et al (2014) Limited role for biliary stent as surrogate fiducial marker in pancreatic cancer: stent and Intratumoral fiducials compared. Int J Radiat Oncol Biol Phys 89(3):641–648
Packard M, Gayou O, Gurram K et al (2015) Use of implanted gold fiducial markers with MV-CBCT image-guided IMRT for pancreatic tumours. J Med Imaging Radiat Oncol 59:499–506
Chortogiannos C, Moseley D, Chen J et al (2017) Evaluation of bony anatomy versus endobiliary stents as surrogates for volumetric image guidance in pancreatic cancer. J Med Imaging Radiat Sci 48:352–359
Dobiasch S, Goerig NL, Fietkau R, Combs SE (2018) Essential role of radtiation therapy for the treatment of pancreatic cancer. Strahlenther Onkol 194:185–195
Van der Horst A, Wognum S, Fajardo RD et al (2013) Interfractional position variation of pancreatic tumors quantified using Intratumoral fiducial markers and daily cone beam computed tomography. Int J Radiat Oncol Biol Phys 87(1):202–208
Varadarajulu S, Trevino JM, Shen S et al (2010) The use of endoscopic ultrasound-guided gold markers in image-guided radiation therapy of pancreatic cancers: a case series. Endoscopy 42:423–425
Versteijne E, Lens E, van der Horst A et al (2017) Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer. Strahlenther Onkol 193:630–638
Mazzola R, Fersino S, Aiello D et al (2018) Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery. Strahlenther Onkol 194:835–842
Panje C, Andratschke N, Brunner TB, Niyazi M, Guckenberger M (2016) Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer. Strahlenther Onkol 192:875–885
Scherman Rydhög J, Jølck RI, Andresen TL et al (2015) Quantification and comparison of visibility and image artifacts of a new liquid fiducial marker in a lung phantom for image-guided radiation therapy. Med Phys 42:2818
Gurney-Champion OJ, Lens E, van der Horst A et al (2015) Visibility and artifacts of gold fiducial markers used for image guided radiation therapy of pancreatic cancer on MRI. Med Phys 42:2638–2647
Schneider S, Jølck RI, Troost EGC et al (2018) Quantification of MRI visibility and artifacts at 3T of liquid fiducial marker in a pancreas tissue-mimicking phantom. Med Phys 45(1):37–47
Giebeler A, Fontenot J, Balter P et al (2009) Dose perturbations from implanted helical gold markers in proton therapy of prostate cancer. J Appl Clin Med Phys 10:2875
Newhauser W, Fontenot J, Koch N et al (2007) Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate. Phys Med Biol 52:2937–2952
Habermehl D, Henkner K, Ecker S et al (2013) Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy. J Radiat Res 54:i61–i68
Scherman Rydhög J, Perrin R, Jølck R et al (2017) Liquid fiducial marker applicability in proton therapy of locally advanced lung cancer. Radiother Oncol 122:393–399
Jølck RI, Binderup T, Hansen AE et al (2014) Injectable colloidal gold in a sucrose acetate isobutyrate gelating matrix with potential use in radiation therapy. Adv Healthc Mater 3:1680–1687
Troost EGC, Menkel S, Enghardt W et al (2017) BioXmark® remains chemically stable following normofractionated and single-fraction high-dose proton beam irradiation. Proceedings to the 56 Annual Meeting of the Particle Therapy Cooperative Group (PTCOG). Int J Part Ther 4(1):75
Dobiasch S, Kampfer S, Burkhardt R et al (2017) BioXmark for high-precision radiotherapy in an orthotopic pancreatic tumor mouse model. Strahlenther Onkol 193:1039–1047
Scherman Rydhög J, Mortensen S, Larsen K et al (2016) Liquid fiducial marker performance during radiotherapy of locally advanced non-small cell lung cancer. Radiother Oncol 121:64–69
De Blanck SR, Scherman-Rydhög J, Larsen KL, al etl (2018) Long term safety and stability and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer. Clin Transl Radiat Oncol 13:24–28
De Blanck SR, Scherman-Rydhög J, Siemsen M, al etl (2018) Feasibility of a novel liquid fiducial marker for use in image guided radiotherapy of oesophageal cancer. Br J Radiol 91(1092):20180236
De Roover R, Crijns W, Poels K et al (2018) Characterization of a novel liquid fiducial marker for multi-modal image guidance in stereotactic body radiotherapy of prostate cancer. Med Phys 45:2205–2217
Mortensen SR, Scherman JB, Larsen KR et al (2014) Use of a novel liquid fiducial marker injected with endoscopic ultrasound equipment for use in image guided radiation therapy of thoracic tumors (porcine model). Int J Radiat Oncol Biol Phys 90(1):S651
Pieper S, Halle M, Kikinis R (2004) 3D slicer. Proceedings of the 1st IEEE International Symposium on Biomedical Imaging: From Nano to Macro. vol 1, pp 632–635
Tanaka O, Nishigaki Y, Hayashi H et al (2017) The advantage of iron-containing fiducial markers placed with a thin needle for radiotherapy of liver cancer in therms of visualization on MRI: an initial experien of Gold Anchor. Radiol Case Rep 12(2):416–421
Marsico M, Gabbani T, Lunardi S, Galli A, Biagini MR, Annese V (2017) Percutaneous ultrasound-guided fiducial marker placement for liver cancer robotic stereotactic radio-surgery treatment: A comparative analysis of three types of markers and needles. Arab J Gastroenterol 18(2):83–86
Larsen MH, Fristrup CW, Detlefsen S, Mortensen MB (2018) Prospective evaluation of EUS-guided fine needle biopsy in pancreatic mass lesions. Endosc Int Open 6(2):E242–E248